Chronic inflammation in FMF: Markers, risk factors, outcomes and therapy

Nature Reviews Rheumatology

Volumn 7, Issue 2, 2011, Pages 105-112

  Ben Zvi, Ilan ^a   Livneh, Avi ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ALPHA2B INTERFERON; C REACTIVE PROTEIN; COLCHICINE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE B4; MACROPHAGE INFLAMMATORY PROTEIN; SERUM AMYLOID A; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; VASCULOTROPIN RECEPTOR 1;

AMYLOIDOSIS; ANEMIA; CHRONIC INFLAMMATION; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE COURSE; DRUG DOSE INCREASE; FAMILIAL MEDITERRANEAN FEVER; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MEDICAL DECISION MAKING; MUSCLE WEAKNESS; MYALGIA; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; QUALITY OF LIFE; REMISSION; REVIEW; RISK FACTOR; SPLENOMEGALY;

BIOLOGICAL MARKERS; CHRONIC DISEASE; COLCHICINE; FAMILIAL MEDITERRANEAN FEVER; GOUT SUPPRESSANTS; HUMANS; INFLAMMATION; RISK FACTORS; SERUM AMYLOID A PROTEIN;

EID: 79651473433     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.181     Document Type: Review

References (91)

1. Livneh, A. et al. The changing face of familial Mediterranean fever. Semin. Arthritis Rheum. 26, 612-627 (1996). (Pubitemid 27024198)
2. French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat. Genet. 17, 25-31 (1997).
3. The International FMF Consortium. Ancient missense mutations in a new member of the roret gene family are likely to cause familial Mediterranean fever. Cell 90, 797-807 (1997).
4. Stojanov, S. & Kastner, D. L. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr. Opin. Rheumatol. 17, 586-599 (2005). (Pubitemid 41527820)
5. Chae, J. J., Aksentijevich, I. & Kastner, D. L. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br. J. Haematol. 146, 467-478 (2009).
6. Dinarello, C. A. Interleukin-1beta and the autoinflammatory diseases. N. Engl. J. Med. 360, 2467-2470 (2009).
7. Kogan, A. et al. Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the carrier state. Am. J. Med. Genet. 102, 272-276 (2001). (Pubitemid 32730278)
8. Celkan, T. et al. The anemia of familial Mediterranean fever disease. Pediatr. Hematol. Oncol. 22, 657-665 (2005). (Pubitemid 41572160)
9. Inal, A., Yilmaz, M., Kendirli, S. G., Altintas, D. U. & Karakoc, G. B. The clinical and genetical features of 124 children with Familial Mediterranean fever: experience of a single tertiary center. Rheumatol. Int. 29, 1279-1285 (2009).
10. Duzova, A. et al. Bone mineral density in children with familial Mediterranean fever. Clin. Rheumatol. 23, 230-234 (2004). (Pubitemid 38812202)
11. Frensdorff, A., Sohar, e. & Heller, H. Plasma fibrinogen in familial Mediterranean fever. Ann. Intern. Med. 55, 448-455 (1961).
12. Zemer, D., Livneh, A., Danon, Y. L., Pras, M. & Sohar, e. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum. 34, 973-977 (1991).
13. Korkmaz, C., Ozdogan, H., Kasapcopur, O. & Yazici, H. Acute phase response in familial Mediterranean fever. Ann. Rheum. Dis. 61, 79-81 (2002). (Pubitemid 34074848)
14. Duzova, A. et al. role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin. Exp. Rheumatol. 21, 509-514 (2003). (Pubitemid 36950324)
15. Lachmann, H. J. et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45, 746-750 (2006). (Pubitemid 43985345)
16. Tunca, M. et al. Acute phase response and evolution of familial Mediterranean fever. Lancet 353, 1415 (1999). (Pubitemid 29192423)
17. Balci, B. et al. MEFV gene mutations in familial Mediterranean fever phenotype II patients with renal amyloidosis in childhood: a retrospective clinicopathological and molecular study. Nephrol. Dial. Transplant. 17, 1921-1923 (2002). (Pubitemid 35277088)
18. Livneh, A. [Amyloidosis of familial Mediterranean fever (FMF) - insights to FMF phenotype II]. Harefuah 145, 743-745, 782 (2006).
19. Karatay, S. et al. Increased serum concentrations of homocysteine and lipoprotein (a) in familial Mediterranean fever. Ann. Clin. Lab. Sci. 40, 10-14 (2010).
20. Clarke, r. et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361, 2518-2528 (2009).
21. Buckley, D. I., Fu, r., Freeman, M., rogers, K. & Helfand, M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the, U. S. Preventive Services Task Force. Ann. Intern. Med. 151, 483-495 (2009).
22. wittkowski, H. et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 58, 3924-3931 (2008).
23. Foell, D., wittkowski, H. & roth, J. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat. Clin. Pract. Rheumatol. 3, 382-390 (2007). (Pubitemid 47034539)
24. Foell, D. et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum. 50, 1286-1295 (2004). (Pubitemid 38480840)
25. Kallinich, T., wittkowski, H., Keitzer, r., roth, J. & Foell, D. Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Ann. Rheum. Dis. 69, 677-82 (2010).
26. Balat, A. et al. Adrenomedullin and total nitrite levels in children with familial Mediterranean fever. J. Paediatr. Child. Health 42, 240-243 (2006). (Pubitemid 43736358)
27. elsasser, T. H. & Kahl, S. Adrenomedullin has multiple roles in disease stress: development and remission of the inflammatory response. Microsc. Res. Tech. 57, 120-129 (2002). (Pubitemid 34438618)
28. Gang, N. et al. Activation of the cytokine network in familial Mediterranean fever. J. Rheumatol. 26, 890-897 (1999). (Pubitemid 29195678)
29. Kiraz, S. et al. effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clin. Exp. Rheumatol. 16, 721-724 (1998). (Pubitemid 28506094)
30. Notarnicola, C., Didelot, M. N., Seguret, F., Demaille, J. & Touitou, I. enhanced cytokine mrNA levels in attack-free patients with familial Mediterranean fever. Genes Immun. 3, 43-45 (2002). (Pubitemid 38961106)
31. Bagci, S. et al. Continuity of cytokine activation in patients with familial Mediterranean fever. Clin. Rheumatol. 23, 333-337 (2004). (Pubitemid 39193790)
32. Haznedaroglu, S. et al. Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever. Clin. Exp. Rheumatol. 23, S77-S80 (2005).
33. Simsek, I. et al. Serum proinflammatory cytokines directing T helper 1 polarization in patients with familial Mediterranean fever. Rheumatol. Int. 27, 807-811 (2007). (Pubitemid 46906637)
34. erken, e., Ozer, H. T. & Gunesacar, r. Plasma interleukin-10 and interleukin-12 levels in patients with familial Mediterranean fever. Rheumatol. Int. 26, 862-864 (2006). (Pubitemid 43881816)
35. Manukyan, G. P. et al. Cytokine profile of Armenian patients with familial Mediterranean fever. Clin. Biochem. 41, 920-922 (2008).
36. Akcan, Y. et al. The importance of serial measurements of cytokine levels for the evaluation of their role in pathogenesis in familial Mediterraean fever. Eur. J. Med. Res. 8, 304-306 (2003).
37. Melamed, A., Cabili, S., Zakuth, v. & Spirer, Z. The immune regulation in familial Mediterranean fever (FMF). J. Clin. Lab. Immunol. 26, 125-128 (1988).
38. Dinarello, C. A. Blocking IL-1 in systemic inflammation. J. Exp. Med. 201, 1355-1359 (2005). (Pubitemid 40664079)
39. rozenbaum, M., Katz, r., rozner, I. & Pollack, S. Decreased interleukin 1 activity released from circulating monocytes of patients with familial Mediterranean fever during in vitro stimulation by lipopolysaccharide. J. Rheumatol. 19, 416-418 (1992).
40. Koklu, S. et al. Interferon-gamma levels in familial Mediterranean fever. Joint Bone Spine 72, 38-40 (2005). (Pubitemid 40169962)
41. Basar, O. et al. Plasma levels of soluble vascular endothelial growth factor receptor-1 (sveGFr-1) in familial Mediterranean fever. Joint Bone Spine 74, 52-55 (2007). (Pubitemid 46240973)
42. rigante, D. et al. Serum macrophage migration inhibitory factor (MIF) in the intercritical phase of hereditary periodic fevers and its relationship with the MIF-173G/C polymorphism. Scand. J. Rheumatol. 36, 307-310 (2007). (Pubitemid 47346918)
43. Direskeneli, H., Ozdogan, H., Korkmaz, C., Akoglu, T. & Yazici, H. Serum soluble intercellular adhesion molecule 1 and interleukin 8 levels in familial Mediterranean fever. J. Rheumatol. 26, 1983-1986 (1999). (Pubitemid 30007068)
44. Bentancur, A. G., Naveh, N., Lancri, J., Selah, B. A. & Livneh, A. Urine leukotriene B4 in familial Mediterranean fever. Clin. Exp. Rheumatol. 22, S56-S58 (2004).
45. Centola, M. et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 95, 3223-3231 (2000). (Pubitemid 30321178)
46. Musabak, U. et al. Does immune activation continue during an attack-free period in familial Mediterranean fever? Clin. Exp. Immunol. 138, 526-533 (2004). (Pubitemid 39573635)
47. Aypar, e. et al. Th1 polarization in familial Mediterranean fever. J. Rheumatol. 30, 2011-2013 (2003). (Pubitemid 37075553)
48. Anton, P. A. et al. enhanced neutrophil chemiluminescence in familial Mediterranean fever. J. Clin. Immunol. 8, 148-156 (1988).
49. Davtyan, T. K., Hakopyan, G. S., Avetisyan, S. A. & Mkrtchyan, N. r. Impaired endotoxin tolerance induction in patients with familial Mediterranean fever. Pathobiology 73, 26-39 (2006). (Pubitemid 43952603)
50. Simon, A. & van der Meer, J. w. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, r86-r98 (2007). (Pubitemid 46089817)
51. Mor, A. et al. evaluation of disease severity in familial Mediterranean fever. Semin. Arthritis Rheum. 35, 57-64 (2005). (Pubitemid 41111472)
52. Gershoni-Baruch, r., Brik, r., Lidar, M., Shinawi, M. & Livneh, A. Male sex coupled with articular manifestations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial Mediterranean fever homozygous for the M694v-MEFV mutation. J. Rheumatol. 30, 308-312 (2003). (Pubitemid 36152595)
53. Gershoni-Baruch, r. et al. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum. 48, 1149-1155 (2003). (Pubitemid 36418258)
54. Padeh, S. et al. Clinical and diagnostic value of genetic testing in 216 Israeli children with familial Mediterranean fever. J. Rheumatol. 30, 185-190 (2003). (Pubitemid 36077792)
55. Berkun, Y. et al. A single testing of serum amyloid A levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin. Arthritis Rheum. 37, 182-188 (2007). (Pubitemid 350161805)
56. Dinarello, C. A., wolff, S. M., Goldfinger, S. e., Dale, D. C. & Alling, D. w. Colchicine therapy for familial mediterranean fever. A double-blind trial. N. Engl. J. Med. 291, 934-937 (1974).
57. Goldfinger, S. e. Colchicine for familial Mediterranean fever. N. Engl. J. Med. 287, 1302 (1972).
58. Zemer, D. et al. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N. Engl. J. Med. 291, 932-934 (1974).
59. Ozcakar, Z. B. et al. Possible effect of subclinical inflammation on daily life in familial Mediterranean fever. Clin. Rheumatol. 25, 149-152 (2006). (Pubitemid 43372309)
60. Zung, A., Barash, G., Zadik, Z. & Barash, J. Familial Mediterranean fever and growth: effect of disease severity and colchicine treatment. J. Pediatr. Endocrinol. Metab. 19, 155-160 (2006). (Pubitemid 43337892)
61. Gough, A. K., Lilley, J., eyre, S., Holder, r. L. & emery, P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344, 23-27 (1994). (Pubitemid 24199420)
62. Harrison, B. J., Hutchinson, C. e., Adams, J., Bruce, I. N. & Herrick, A. L. Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. Ann. Rheum. Dis. 61, 1007-1011 (2002). (Pubitemid 35221691)
63. Carbone, L., Tylavsky, F., wan, J., McKown, K. & Cheng, S. Bone mineral density in scleroderma. Rheumatology (Oxford) 38, 371-372 (1999).
64. Yuksel, S. et al. Increased serum osteoprotegerin levels associated with decreased bone mineral density in familial Mediterranean fever. Tohoku J. Exp. Med. 217, 321-327 (2009).
65. Suyani, e. et al. Decreased bone mineral density in adult familial Mediterranean fever patients: a pilot study. Clin. Rheumatol. 27, 1171-1175 (2008).
66. Yildirim, K. et al. Bone mineral density in patients with familial Mediterranean fever. Rheumatol. Int. 30, 305-308 (2010).
67. Buskila, D. et al. Quality of life of patients with familial Mediterranean fever. Clin. Exp. Rheumatol. 15, 355-360 (1997). (Pubitemid 27323995)
68. Makay, B., Unsal, e., Arslan, N. & varni, J. w. Health-related quality of life of school-age children with familial Mediterranean fever. Clin. Exp. Rheumatol. 27, S96-S101 (2009).
69. Deger, S. M. et al. Health-related quality of life and its associations with mood condition in familial Mediterranean fever patients. Rheumatol. Int. doi:10.1007/s00296-009-1334-1334.
70. Gimeno, D. et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the whitehall II study. Psychol. Med. 39, 413-423 (2009).
71. ehrenfeld, M., Brzezinski, A., Levy, M. & eliakim, M. Fertility and obstetric history in patients with familial Mediterranean fever on long-term colchicine therapy. Br. J. Obstet. Gynaecol. 94, 1186-1191 (1987). (Pubitemid 18058559)
72. Ismajovich, B., Zemer, D., revach, M., Serr, D. M. & Sohar, e. The causes of sterility in females with familial Mediterranean fever. Fertil. Steril. 24, 844-847 (1973).
73. Ofir, D., Levy, A., wiznitzer, A., Mazor, M. & Sheiner, e. Familial Mediterranean fever during pregnancy: an independent risk factor for preterm delivery. Eur. J. Obstet. Gynecol. Reprod. Biol. 141, 115-118 (2008).
74. Ben-Chetrit, e. & Levy, M. reproductive system in familial Mediterranean fever: an overview. Ann. Rheum. Dis. 62, 916-919 (2003). (Pubitemid 37159485)
75. Caliskan, M. et al. Impaired coronary microvascular function in familial Mediterranean fever. Atherosclerosis 195, e161-e167 (2007). (Pubitemid 350087982)
76. Tavil, Y. et al. The detailed assessment of left and right ventricular functions by tissue Doppler imaging in patients with familial Mediterranean fever. Clin. Rheumatol. 27, 189-194 (2008).
77. Akdogan, A. et al. Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF. J. Am. Coll. Cardiol. 48, 2351-2353 (2006). (Pubitemid 44855439)
78. Terekeci, H. M. et al. Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF? J. Rheumatol. 35, 2024-2029 (2008).
79. Bilginer, Y. et al. evaluation of intima media thickness of the common and internal carotid arteries with inflammatory markers in familial Mediterranean fever as possible predictors for atherosclerosis. Rheumatol. Int. 28, 1211-1216 (2008).
80. Ugurlu, S. et al. Intima-media thickening in patients with familial Mediterranean fever. Rheumatology (Oxford) 48, 911-915 (2009).
81. Grimaldi, M. P. et al. role of the pyrin M694v (A2080G) allele in acute myocardial infarction and longevity: a study in the Sicilian population. J. Leukoc. Biol. 79, 611-615 (2006). (Pubitemid 44831237)
82. Langevitz, P. et al. Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr. Med. Assoc. J. 3, 9-12 (2001). (Pubitemid 34176872)
83. Heller, H., Sohar, e., Gafni, J. & Heller, J. Amyloidosis in familial Mediterranean fever. An independent genetically determined character. Arch. Intern. Med. 107, 539-550 (1961).
84. Knecht, A., de Beer, F. C. & Pras, M. Serum amyloid A protein in familial Mediterranean fever. Ann. Intern. Med. 102, 71-72 (1985). (Pubitemid 15187662)
85. Zemer, D., Pras, M., Sohar, e. & Gafni, J. Colchicine in familial Mediterranean fever. N. Engl. J. Med. 294, 170-171 (1976).
86. Tweezer-Zaks, N., rabinovich, e., Lidar, M. & Livneh, A. Interferon-alpha as a treatment modality for colchicine-resistant familial Mediterranean fever. J. Rheumatol. 35, 1362-1365 (2008). (Pubitemid 352000785)
87. Lidar, M. et al. The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. J. Rheumatol. 33, 1089-1092 (2006). (Pubitemid 43825457)
88. Mor, A., Pillinger, M. H., Kishimoto, M., Abeles, A. M. & Livneh, A. Familial Mediterranean fever successfully treated with etanercept. J. Clin. Rheumatol. 13, 38-40 (2007). (Pubitemid 46213843)
89. rilonacept for treatment of familial Mediterranean fever. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT00582907 (2010).
90. Gillmore, J. D., Lovat, L. B., Persey, M. r., Pepys, M. B. & Hawkins, P. N. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358, 24-29 (2001). (Pubitemid 32709735)
91. Lachmann, H. J. et al. Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 356, 2361-2371 (2007). (Pubitemid 46883770)